S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
NFLX   342.88 (-2.91%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
NFLX   342.88 (-2.91%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
NFLX   342.88 (-2.91%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
NFLX   342.88 (-2.91%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
Log in

LON:DDDD - 4d Pharma Share Price, Forecast & News

GBX 93.50
-3.75 (-3.86 %)
(As of 01/27/2020 04:00 PM ET)
Today's Range
93.23
Now: GBX 93.50
97.40
50-Day Range
96
MA: GBX 100.16
110.80
52-Week Range
65
Now: GBX 93.50
147.50
Volume19,522 shs
Average Volume16,686 shs
Market Capitalization£61.24 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
4D pharma plc engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease, as well as Rosburix for Paediatric Ulcerative Colitis. It also develops immuno-oncology products, including MRx0518 for solid tumors; respiratory products, such as MRx0004 for asthma and MRx0001 for allergic asthma; autoimmune products comprising MRx0002 for multiple sclerosis and MRx0006 for rheumatoid arthritis; and CNS products for autism. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of KEYTRUDAÂ and MRx0518 in patients with solid tumours. The company was formerly known as Schosween 18 Limited. 4D pharma plc was founded in 2014 and is headquartered in Leeds, the United Kingdom.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-113-8950130

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 18.24 per share
Book ValueGBX 53.40 per share

Profitability

Miscellaneous

Employees93
Market Cap£61.24 million
Next Earnings DateN/A
OptionableNot Optionable

Receive DDDD News and Ratings via Email

Sign-up to receive the latest news and ratings for DDDD and its competitors with MarketBeat's FREE daily newsletter.


4d Pharma (LON:DDDD) Frequently Asked Questions

What is 4d Pharma's stock symbol?

4d Pharma trades on the London Stock Exchange (LON) under the ticker symbol "DDDD."

Has 4d Pharma been receiving favorable news coverage?

News headlines about DDDD stock have trended somewhat negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. 4d Pharma earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for 4d Pharma.

Who are some of 4d Pharma's key competitors?

What other stocks do shareholders of 4d Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other 4d Pharma investors own include Cray (CRAY), Oracle (ORCL), Universal Health Services (UHS), Amigo (AMGO), Ashtead Group (AHT), Telefonica Deutschland (O2D), Fresenius Medical Care AG & Co. KGaA (FME), Bayerische Motoren Werke (BMW), Rifco (RFC) and Prize Mining (PRZ).

Who are 4d Pharma's key executives?

4d Pharma's management team includes the folowing people:
  • Mr. Duncan Joseph Peyton, CEO & Exec. Director (Age 49)
  • Dr. Alexander James Stevenson, Chief Scientific Officer & Exec. Director (Age 47)
  • Mr. Stephen Dunbar, Fin. Director
  • Fay Weston, Head of Investor Relations
  • Mr. Laurence Dale, Gen. Counsel & Company Sec.

How do I buy shares of 4d Pharma?

Shares of DDDD and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is 4d Pharma's stock price today?

One share of DDDD stock can currently be purchased for approximately GBX 93.50.

How big of a company is 4d Pharma?

4d Pharma has a market capitalization of £61.24 million. 4d Pharma employs 93 workers across the globe.View Additional Information About 4d Pharma.

What is 4d Pharma's official website?

The official website for 4d Pharma is http://www.4dpharmaplc.com/.

How can I contact 4d Pharma?

4d Pharma's mailing address is 9 Bond Court, LEEDS, LS1 2JZ, United Kingdom. The company can be reached via phone at +44-113-8950130.


MarketBeat Community Rating for 4d Pharma (LON DDDD)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  38 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about 4d Pharma and other stocks. Vote "Outperform" if you believe DDDD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DDDD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel